|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Myokardia Inc (MYOK)
WEIGHTED MOVING AVERAGE
Trading: BUY @ $65.15
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.
Myokardia Inc (NASDAQ:MYOK) currently has a confirmed uptrend. Recent trading has caused the WMA 15 day average to exceed the closing price confirming the short term trend following indicator. Currently, the return on WMA15 is 0.5%.
Weighted moving averages (WMA) are difficult to construct but more reliable than the simple moving averages. WMA permits an unequal weighting on prior time periods.
Calculation: Weighted Moving Average (WMA):
1) Ft= W1At-1 + WnAt-n
PROFILE: Myokardia Inc (MYOK)
Stock Exchange: NASDAQ
Company: Myokardia Inc
Ticker Codes: | MYOK | NASDAQ:MYOK |
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a strategic collaboration with Aventis Inc. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
|BCRX BioCryst Pharmaceuticals||2.85||10.3||2,873,485||0.3||BULLISH|
|AUPH Aurinia Pharmaceuticals||7.94||9.8||2,695,366||4.3||BULLISH|
|STKL Sunopta Inc||2.9||7.4||191,000||3||BULLISH|
|WVE WAVE Life Sciences||33.15||5.9||191,800||1.8||BULLISH|
|MRUS Merus NV||16.48||5||77,000||16.5||BULLISH|
|DHXM DHX Media Ltd||1.27||5||217,745||1.8||BULLISH|
|FPRX Five Prime||3.92||3.7||178,700||5.3||BULLISH|
|EDIT Editas Medicine||30.28||3.6||1,703,036||1.4||BULLISH|
|HSTM Healthstream Inc||29.13||3.6||203,106||1||BULLISH|